THERAPY DOSSIER · th-b294cf9dd4b6

Caragana tangutica KOM ethyl acetate extract

Nutraceutical · Botanical extract (Caragana tangutica); not a ChEMBL entity

Evidence & regulatory context

Mechanism: Botanical extract (Caragana tangutica); not a ChEMBL entity
Target: Not recorded
Injury models: Endotoxin/LPS
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 24406787 ↗2014Reported benefit

The anti-inflammatory effects of Caragana tangutica ethyl acetate extract.

MixedEndotoxin/LPSSprague-Dawley (rats)Male100, 200 and 400 mg/kg

Model: Lipopolysaccharide-induced acute lung injury in mice, with xylene-induced ear oedema, carrageenan-induced paw oedema and acetic acid-induced writhing models

The extract significantly reduced xylene-induced ear oedema at 100, 200 and 400 mg/kg, reduced carrageenan-induced paw oedema at 3 hours, reduced acetic acid writhing dose-dependently, and reduced lipopolysaccharide-induced acute lung injury through inhibition of prostaglandin E2 release and COX-2…

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…